About this trial
The prevalence of age-related chronic diseases (like obesity, type 2 diabetes and cardiovascular diseases) is mounting worldwide, reaching pandemic proportions. These age-related chronic diseases are associated with diminished skeletal muscle mitochondrial function in humans. Nicotinamide adenosine dinucleotide (NAD) is a coenzyme that regulates mitochondrial function, therefore, plays an important role in energy metabolism. Importantly, it has been shown that high cellular NAD+ levels as well as a high NAD+/NADH ratio promote metabolic and mitochondrial health. In contrast, NAD+ bioavailability declines upon aging in humans as well as in animal models of metabolic disorders and type 2 diabetes. These findings fuel the notion of boosting the NAD+ bioavailability in order to improve metabolic disturbances and mitochondrial dysfunction in aged individuals. Supplementation with nicotinamide riboside (NR), a naturally occurring form of vitamin B3, boosts cellular NAD+ levels. However, in contrast to animal studies, NR supplementation in humans has so far been unsuccessful in improving skeletal muscle mitochondrial function, exercise capacity or insulin sensitivity. Interestingly, Recently, it has been suggested that metabolic conditions where NAD+ levels become limited, is needed for NR supplementation to exert beneficial health effects. This metabolic condition could be achieved by exercise. However, studies combining NR and exercise are lacking, and that is why we will perform the present study.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Participants are able to provide signed and dated written informed consent prior to any study specific procedures
Aged ≥ 60 and ≤ 80 years
Body mass index (BMI) 25 - 35 kg/m2
Stable dietary habits (no weight loss or gain > 5 kg in the past 3 months)
Disqualifiers
Patients with congestive heart failure and and/or severe renal and or liver insufficiency
Uncontrolled hypertension
Any contra-indication for MRI scanning
Alcohol consumption of > 3 servings per day for man and >2 servings per day for woman
Trial design
Parallel
Treatments tested in this trial
Nicotinamide Riboside (NR)
Dietary supplementParticipants will ingest 1g/d of NR orally during 12 weeks in parallel to a exercise training program
Placebo
Dietary supplementParticipants will ingest 1g/d of placebo orally during 12 weeks in parallel to a exercise training program
Treatment groups
Trial outcomes
Primary outcomes
Skeletal muscle mitochondrial respiratory capacity
Skeletal muscle mitochondrial respiratory capacity will be measured in permeabilized fibres.
Secondary outcomes
Quantification of proteins that regulate oxidative metabolism
Quantification of proteins content of oxidative phosphorylation system in muscle biopsies
Skeletal muscle mitochondrial content
Proteins content of oxidative phosphorylation system will be quantified from muscle biopsy
Maximal aerobic capacity
Maximal aerobic capacity will be measure upon a progressive cycling test
Walking speed and distance
Walking speed and distance will be measured via the 6-minutes walking test
Sponsors and contacts
Click on the lead sponsor to view all of their trials.